Cencora, Inc. $COR Stock Holdings Raised by Allstate Corp

Allstate Corp raised its stake in Cencora, Inc. (NYSE:COR) by 110.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 14,102 shares of the company’s stock after acquiring an additional 7,398 shares during the period. Allstate Corp’s holdings in Cencora were worth $4,763,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Cencora by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after purchasing an additional 221,570 shares during the last quarter. State Street Corp increased its position in shares of Cencora by 9.3% in the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after purchasing an additional 782,911 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after purchasing an additional 821,098 shares during the last quarter. Boston Partners increased its position in shares of Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after purchasing an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Cencora by 3.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock worth $1,241,094,000 after purchasing an additional 115,278 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $271.84 on Wednesday. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm has a 50-day simple moving average of $302.59 and a 200 day simple moving average of $335.67. The company has a market cap of $52.89 billion, a PE ratio of 20.85, a P/E/G ratio of 1.27 and a beta of 0.64.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the company posted $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has approved a stock repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a $0.60 dividend. The ex-dividend date is Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Evercore set a $360.00 target price on shares of Cencora in a research report on Wednesday, April 8th. Barclays boosted their price objective on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Morgan Stanley set a $342.00 price objective on shares of Cencora in a research report on Friday, May 8th. Finally, Wells Fargo & Company lowered their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.